{"id":22990,"date":"2024-11-06T06:08:00","date_gmt":"2024-11-05T22:08:00","guid":{"rendered":"https:\/\/www.franchise.com.hk\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990"},"modified":"2024-11-06T06:08:00","modified_gmt":"2024-11-05T22:08:00","slug":"%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6","status":"publish","type":"post","link":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990","title":{"rendered":"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a"},"content":{"rendered":"<p><span class=\"legendSpanClass\">\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde<\/span><span class=\"legendSpanClass\">2024\u5e7411\u67086\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c66\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a\u3002\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c7\u5e74\u5165\u9078ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\uff0c\u5145\u5206\u9ad4\u73fe\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u5176\u7642\u6548\u548c\u5b89\u5168\u6027\u7684\u8a8d\u53ef\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\uff0c\u516c\u53f8\u56db\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u3001APG-2575\u3001APG-2449\u3001APG-5918\uff09\u6709\u591a\u9805\u81e8\u5e8a\u548c\u81e8\u5e8a\u524d\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u4e26\u7372\u5169\u9805\u53e3\u982d\u5831\u544a\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>\u8010\u7acb\u514b\u662f\u4e9e\u76db\u91ab\u85e5\u81ea\u4e3b\u7814\u767c\u7684\u5168\u7403\u5c64\u9762best-in-class\u6f5b\u529b\u85e5\u7269\uff0c\u70ba\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR:ABL\u6291\u5236\u5291\uff0c\u8a72\u54c1\u7a2e\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u516c\u53f8\u5c07\u5728\u6b64\u6b21ASH\u5e74\u6703\u4e0a\uff0c\u53e3\u982d\u5831\u544a\u5176\u7528\u65bc\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u4e8c\u7dda\u6cbb\u7642\u7684\u7814\u7a76\u6700\u65b0\u9032\u5c55\uff0c\u8a72\u7814\u7a76\u4e3b\u8981\u7814\u7a76\u8005\u70ba\u6b66\u6f22\u5354\u548c\u91ab\u9662\u9ece\u7def\u660e\u6559\u6388\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u6d77\u5916\u81e8\u5e8a\u7814\u7a76\u7684\u6700\u65b0\u9032\u5c55\u3001\u4ee5\u53ca\u8a72\u54c1\u7a2e\u806f\u5408\u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2eBcl-2\u6291\u5236\u5291APG-2575\uff08lisaftoclax\uff09\u6cbb\u7642\u5fa9\u767c\/\u96e3\u6cbb\u6027\uff08R\/R\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u5152\u7ae5\u60a3\u8005\u7684\u7814\u7a76\u6578\u64da\u4e5f\u5c07\u4ee5\u58c1\u5831\u5c55\u793a\u5f62\u5f0f\u516c\u4f48\u3002<\/p>\n<p>\u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u6703\u662f\u5168\u7403\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u5b78\u8853\u76db\u6703\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u84cb\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7642\u7814\u7a76\u3002\u7b2c66\u5c46ASH\u5e74\u6703\u5c07\u65bc\u7576\u5730\u6642\u95932024\u5e7412\u67087\u65e5\u81f310\u65e5\u9593\u5728\u7f8e\u570b\u8056\u5730\u4e9e\u54e5\u4ee5\u7dda\u4e0b\u7d50\u5408\u7dda\u4e0a\u7684\u5f62\u5f0f\u8209\u884c\u3002<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4eca\u5e74\u5c07\u662f\u8010\u7acb\u514b\u9023\u7e8c\u7b2c7\u5e74\u5728ASH\u5e74\u6703\u4e0a\u5c55\u793a\u6700\u65b0\u81e8\u5e8a\u9032\u5c55\uff0c\u53c8\u4e00\u6b21\u5237\u65b0\u5176\u53e3\u982d\u5831\u544a\u9023\u7e8c\u5165\u9078\u8a18\u9304\uff0c\u9ad4\u73fe\u4e86\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u8010\u7acb\u514b\u9019\u4e00\u5168\u7403\u5c64\u9762best-in-class\u6f5b\u529b\u85e5\u7269\u7684\u5de8\u5927\u8a8d\u53ef\u3002\u6b64\u5916\uff0c\u4eca\u5e74\uff0c\u516c\u53f8\u56db\u500b\u91cd\u9ede\u54c1\u7a2e\u6709\u591a\u9805\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5145\u5206\u986f\u73fe\u4e86\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u548c\u958b\u767c\u5be6\u529b\u3002\u6211\u5011\u671f\u5f85\u5728\u5f8c\u7e8c\u6703\u8b70\u671f\u9593\u8207\u5927\u5bb6\u5206\u4eab\u76f8\u95dc\u7814\u7a76\u7684\u8a73\u5be6\u6578\u64da\u3002\u672a\u4f86\uff0c\u4e9e\u76db\u91ab\u85e5\u5c07\u9032\u4e00\u6b65\u52a0\u901f\u63a8\u9032\u81e8\u5e8a\u958b\u767c\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d<\/p>\n<p>ASH 2024\u4e9e\u76db\u91ab\u85e5\u7522\u54c1\u76f8\u95dc\u7814\u7a76\u4e00\u89bd\uff1a<\/p>\n<div>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5c55\u793a\u5f62\u5f0f\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u54c1\u7a2e<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u6458\u8981\u6a19\u984c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u7de8\u865f\u00a0<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u53e3\u982d\u5831\u544a<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib as Second-Line (2L) Therapy in Patients <br \/>(pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-<br \/>CML)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3<br \/>\u8005\u7684\u4e8c\u7dda\u6cbb\u7642<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">480<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08Lisaftoclax\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Lisaftoclax (APG-2575) Combined with Novel Therapeutic <br \/>Regimens in Patients (pts) with Relapsed or\u00a0Refractory <br \/>Multiple Myeloma (R\/R MM) or Immunoglobulin Light-<br \/>Chain (AL) Amyloidosis<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Lisaftoclax\uff08APG-2575\uff09\u806f\u5408\u65b0\u578b\u6cbb\u7642\u65b9\u6848\u7528\u65bc\u5fa9\u767c\/\u96e3<br \/>\u6cbb\u6027\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08R\/R MM\uff09\u6216\u514d\u75ab\u7403\u86cb\u767d\u8f15\u93c8<br \/>\uff08AL\uff09\u6fb1\u7c89\u6a23\u8b8a\u6027\u60a3\u8005\uff08pts\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1022<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u58c1\u5831\u5c55\u793a<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib (HQP1351) Overcomes <\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Resistance\/Intolerance to Asciminib and Ponatinib in <br \/>Patients (pts) with Heavily Pretreated Chronic-Phase <br \/>Chronic Myeloid Leukemia (CP CML): A 1.5-Year\u00a0Follow-up <br \/>Update with Comprehensive Exposure-Response (E-R) <br \/>Analyses<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u53ef\u514b\u670d\u7d93\u6df1\u5ea6\u6cbb\u7642\u7684\u6162\u6027\u671f\u6162<br \/>\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP CML\uff09\u60a3\u8005\u5c0dAsciminib\u548c<br \/>Ponatinib\u7684\u8010\u85e5\/\u4e0d\u8010\u53d7\uff1a\u4f86\u81ea1.5\u5e74\u96a8\u8a2a\u7684\u6700\u65b0\u6578\u64da\u53ca<br \/>\u7d9c\u5408\u66b4\u9732-\u53cd\u61c9\uff08E-R\uff09\u5206\u6790<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">3151<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08Lisaftoclax\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Lisaftoclax (APG-2575) Demonstrates Activity and Safety <br \/>When Given with Accelerated Ramp-up and then Combined <br \/>with Acalabrutinib or Rituximab in Patients (pts) with <br \/>Chronic Lymphocytic Leukemia\/Small Lymphocytic <br \/>Lymphoma (CLL\/SLL),\u00a0Including Those with Prior Exposure <br \/>to Venetoclax<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Lisaftoclax\uff08APG-2575\uff09\u5728\u5feb\u901f\u5291\u91cf\u905e\u589e\u7d66\u85e5\u5f8c\u8207\u963f\u53ef\u66ff<br \/>\u5c3c\u6216\u5229\u59a5\u6614\u55ae\u6297\u806f\u5408\u6cbb\u7642\u5728\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb<br \/>\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6297\u816b\u7624\u6d3b<br \/>\u6027\uff0c\u5305\u62ec\u65e2\u5f80\u63a5\u53d7\u7dad\u5948\u514b\u62c9\u6cbb\u7642\u7684\u60a3\u8005<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">4614<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08Lisaftoclax\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in <br \/>Combination with Azacitidine in Treatment of Patients with <br \/>Myelodysplastic\u00a0Syndrome (MDS)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u65b0\u578bBcl-2\u6291\u5236\u5291Lisaftoclax\uff08APG-2575\uff09\u806f\u5408\u963f\u624e\u80de\u7518<br \/>\u6cbb\u7642\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">3202<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">+<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Safety and Efficacy of Olverembatinib (HQP1351) Combined <br \/>with Lisaftoclax (APG-2575) in Children and Adolescents <br \/>with\u00a0Relapsed\/Refractory Philadelphia Chromosome\u2013<br \/>Positive Acute Lymphoblastic Leukemia (R\/R Ph+ ALL): First <br \/>Report from\u00a0a Phase 1 Study<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Lisaftoclax\uff08APG-2575\uff09<br \/>\u6cbb\u7642\u5fa9\u767c\/\u96e3\u6cbb\u6027\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08R\/R Ph+ ALL\uff09<br \/>\u5152\u7ae5\u53ca\u9752\u5c11\u5e74\u60a3\u8005\u7684\u5b89\u5168\u6027\u548c\u7642\u6027\uff1a\u4e00<br \/>\u9805I\u671f\u81e8\u5e8a\u7814\u7a76\u7684\u9996\u6b21\u5831\u544a\u3002<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1443<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">A Phase 2 Study of Olverembatinib for the Treatment of <br \/>Myeloid\/Lymphoid Neoplasms with FGFR1 <br \/>Rearrangement<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u4e00\u9805\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u651c\u5e36FGFR1\u57fa\u56e0\u91cd\u6392\u7684\u9ad3\u7d30<br \/>\u80de\/\u6dcb\u5df4\u7d30\u80de\u816b\u7624\u7684II\u671f\u81e8\u5e8a\u7814\u7a76<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1781<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib 30 Mg Versus 40 Mg Every Other Day <br \/>(QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) <br \/>Resistant or\u00a0Intolerant Chronic-Phase Chronic Myeloid <br \/>Leukemia (CML-CP): A Multi-Center Propensity Score-<br \/>Matched Analysis<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u9694\u5929\u4e00\u6b21\uff08QOD\uff0930mg\u8f03QOD 40mg\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb<br \/>\u7642\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u6216\u4e0d\u8010\u53d7\u7684\u6162\u6027\u671f<br \/>\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CML-CP\uff09\u60a3\u8005\uff1a\u4e00\u9805\u591a\u4e2d\u5fc3\u50be\u5411<br \/>\u5f97\u5206\u5339\u914d\u5206\u6790<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">4529<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Combination of Olverembatinib and VP Regimen for <br \/>Newly Diagnosed Adult Philadelphia Chromosome-<br \/>Positive Acute\u00a0Lymphoblastic Leukemia<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408VP\u65b9\u6848\u6cbb\u7642\u65b0\u8a3a\u65b7\u7684\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d<br \/>\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\u6210\u4eba\u60a3\u8005<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1449<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib-Therapy in Patients with Accelerated-<br \/>Phase Chronic Myeloid Leukaemia: A Multi-Centre <br \/>Retrospective\u00a0Study from China<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u52a0\u901f\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u4e00\u9805\u5728\u4e2d<br \/>\u570b\u958b\u5c55\u7684\u591a\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1767<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\uff08HQP1351\uff09<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib-Based Therapy in Patients with <br \/>Philadelphia Chromosome-Positive Acute Leukemia: A <br \/>Multi-Centre\u00a0Retrospective Study from China<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u57fa\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u7642\u6cd5\u6cbb\u7642\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u767d\u8840<br \/>\u75c5\uff1a\u4e00\u9805\u5728\u4e2d\u570b\u958b\u5c55\u7684\u591a\u4e2d\u5fc3\u56de\u9867\u6027\u7814\u7a76<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">4528<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">+<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2449<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2449, a Novel Focal Adhesion Kinase (FAK) Inhibitor, <br \/>Exhibits Antileukemic Activity and Enhances Lisaftoclax <br \/>(APG-2575)-Induced Apoptosis in Acute Myeloid Leukemia<br \/>(AML)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u65b0\u578b\u5c40\u7076\u6027\u9ecf\u9644\u6fc0\u9176\uff08FAK\uff09\u6291\u5236\u5291APG-2449\u5728\u6025\u6027\u9ad3<br \/>\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u4e2d\u986f\u793a\u4e86\u6297\u767d\u8840\u75c5\u6d3b\u6027\u4e26\u5f37\u5316\u4e86\u7531<br \/>Lisaftoclax\uff08APG-2575\uff09\u8a98\u5c0e\u7684\u7d30\u80de\u51cb\u4ea1<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">4150<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-5918<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Embryonic Ectoderm Development (EED) Inhibitor APG-<br \/>5918 Demonstrates Robust Antitumor Activity in Preclinical <br \/>Models\u00a0of T-Cell Lymphomas (TCLs)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\u86cb\u767d\uff08EED\uff09\u6291\u5236\u5291APG-5918\u5728T\u7d30\u80de<br \/>\u6dcb\u5df4\u7624\uff08TCL\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u986f\u793a\u4e86\u5f37\u6548\u7684\u6297\u816b\u7624\u6d3b\u6027<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">1415<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5728\u7dda\u767c\u4f48<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">+<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">APG-2575<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Olverembatinib (HQP1351) in Combination with Lisaftoclax <br \/>Overcomes Venetoclax Resistance in Preclinical Model of <br \/>Acute Myeloid Leukemia (AML)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Lisaftoclax\uff08APG-2575\uff09<br \/>\u53ef\u5728\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d<br \/>Venetoclax\u8010\u85e5<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">5777<\/span><\/p>\n<\/div>\n<p>\u00a0<\/p>\n<p>\u8010\u7acb\u514b\u5165\u90782024 ASH\u5e74\u6703\u7684\u4e3b\u8981\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08APG-2575\u5165\u9078ASH\u5e74\u6703\u7684\u6458\u8981\u8a73\u7d30\u4fe1\u606f\u53c3\u898b\u540c\u671f\u767c\u4f48\u7684\u53e6\u4e00\u7bc7\u65b0\u805e\u7a3f\uff09<\/p>\n<p>\u53e3\u982d\u5831\u544a<\/p>\n<p>Olverembatinib as Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)<br \/>\u5967\u96f7\u5df4\u66ff\u5c3c\u7528\u65bc\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP-CML\uff09\u60a3\u8005\u7684\u4e8c\u7dda\u6cbb\u7642<\/p>\n<p>\u5c55\u793a\u5f62\u5f0f\uff1a\u53e3\u982d\u5831\u544a<\/p>\n<p>\u6458\u8981\u7de8\u865f\uff1a480<\/p>\n<p>\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u65b0\u578b\u85e5\u7269\u7684\u81e8\u5e8a\u61c9\u7528<\/p>\n<p>\u5831\u544a\u6642\u9593\uff1a<\/p>\n<p>2024\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0a\u53489:30 &#8211; 11:00\uff08\u7f8e\u570b\u897f\u90e8\u6642\u9593\uff09<br \/>2024\u5e7412\u67089\u65e5\uff0c\u661f\u671f\u4e00\uff1b\u51cc\u66681:30 \u2013 3:30\uff08\u5317\u4eac\u6642\u9593\uff09<\/p>\n<p>\u7b2c\u4e00\u4f5c\u8005\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662\u00a0\u9ece\u7def\u660e\u6559\u6388<\/p>\n<p>\u6838\u5fc3\u8981\u9ede\uff1a<\/p>\n<p>\u7814\u7a76\u80cc\u666f\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u662f\u7b2c\u4e09\u4ee3\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\uff0c\u5728\u8010\u85e5\u548c\uff08\u6216\uff09\u4e0d\u8010\u53d7\u81f3\u5c112\u7a2eTKI\u6216\u4f34\u6709T315I\u7a81\u8b8a\u7684CML\u60a3\u8005\u4e2d\u986f\u793a\u51fa\u7a81\u51fa\u7684\u7642\u6548\u548c\u826f\u597d\u7684\u5b89\u5168\u6027\u3002\u672c\u7814\u7a76\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642\u7121T315I\u7a81\u8b8a\u7684CP-CML\u60a3\u8005\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002<\/p>\n<p>\u7814\u7a76\u4ecb\u7d39\uff1a\u9019\u662f\u4e00\u9805\u91dd\u5c0d\u65e2\u5f80\u4f7f\u7528\u904e\u4e00\u7a2eTKI\u6cbb\u7642\u5f8c\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff08\u5305\u62ec\u4f0a\u99ac\u66ff\u5c3c\u3001\u6c1f\u99ac\u66ff\u5c3c\u3001\u5c3c\u6d1b\u66ff\u5c3c\u53ca\u9054\u6c99\u66ff\u5c3c\u7b49\uff09\u7684CML-CP\u60a3\u8005\u7684\u958b\u653e\u6027\u3001\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u9694\u65e5\u53e3\u670d40mg\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u4e00\u7a2eTKI\u6cbb\u7642\u8010\u85e5\/\u4e0d\u8010\u53d7\u7684\u975eT315I \u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3001\u5b89\u5168\u6027\u53ca\u60a3\u8005\u751f\u6d3b\u8cea\u91cf\u3002<\/p>\n<p>\u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a\u00a0\u622a\u81f32024\u5e747\u670829\u65e5\uff0c\u5171\u5165\u7d44\u975eT315I \u7a81\u8b8a\u7684CML-CP \u60a3\u800542\u4f8b\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u63a1\u7528\u9694\u65e5\u7d66\u85e5\uff08QOD\uff09\u7684\u65b9\u5f0f\uff0c28\u5929\u70ba\u4e00\u500b\u9031\u671f\u3002<\/p>\n<p>\u7642\u6548\u6578\u64da\uff1a<\/p>\n<p>\u622a\u81f32024\u5e747\u670829\u65e5\uff0c33\u4f8b\uff0878.6%\uff09\u60a3\u8005\u63a5\u53d7\u4e86\u81f3\u5c111\u6b21\u7642\u6548\u8a55\u4f30\uff0c28\u4f8b\uff0866.7%\uff09\u63a5\u53d7\u4e86\u81f3\u5c112\u6b21\u7642\u6548\u8a55\u4f30\uff0c23\u4f8b\uff0854.8%\uff09\u63a5\u53d7\u4e86\u81f3\u5c113\u6b21\u7642\u6548\u8a55\u4f30\u30023\u4f8b\u60a3\u8005\u5c1a\u672a\u9032\u884c\u9996\u6b21\u7642\u6548\u8a55\u4f30\u3002   \u81f3\u622a\u6b62\u65e5\u671f\uff0c75.0%\uff0824\/32\uff09\u7684\u60a3\u8005\u7372\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\uff0c40.6%\uff0813\/32\uff09\u7372\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u3002\u7b2c6\u30019\u300112\u300118\u500b\u9031\u671f\u8a55\u4f30\u7684CCyR\u7387\u548cMMR\u7387\u5206\u5225\u70ba53.4%\u548c28.6%\u300164.8%\u548c32.5%\u300169.1%\u548c32.5%\u300177.7%\u548c43.9%\uff0c\u63d0\u793a\u7642\u6548\u96a8\u7528\u85e5\u6642\u9593\u5ef6\u9577\u800c\u6539\u5584\u3002   \u572832\u4f8b\u7642\u6548\u53ef\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c\u670923\u4f8b\u66fe\u4ee5\u7b2c\u4e8c\u4ee3TKI\u4f5c\u70ba\u4e00\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d19\u4f8b\uff0882.68%\uff09\u7372CCyR\uff0c10\u4f8b\uff0843.5%\uff09\u7372MMR\uff1b\u5728\u65e2\u5f80\u63a5\u53d7\u4f0a\u99ac\u66ff\u5c3c\u6cbb\u7642\u76849\u4f8b\u60a3\u8005\u4e2d\uff0c5\u4f8b\u7372CCyR\uff0855.6%)\uff0c3\u4f8b\u7372MMR\uff0833.3%\uff09\u3002  <\/p>\n<p>\u5b89\u5168\u6027\u6578\u64da\uff1a\u4e2d\u4f4d\uff08\u5340\u9593\uff09\u6cbb\u7642\u6642\u959316.0\uff081 ~ 18\uff09\u500b\u6708\u3002\u5171\u670937\u4f8b\uff0888.1%\uff09\u60a3\u8005\u767c\u751f\u4e86\u4efb\u4f55\u7d1a\u5225\u7684\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5176\u4e2d19\u4f8b\uff0845.2%\uff09\u767c\u751f\u4e86\u22653\u7d1aTRAEs\uff0c5\u4f8b\uff0811.9%\uff09\u767c\u751f\u4e86\u8207\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dc\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\uff08SAEs\uff09\u3002\u975e\u8840\u6db2\u5b78TRAEs\u5305\u62ec\u76ae\u819a\u8272\u7d20\u6c89\u8457\uff0838.1%\uff09\u3001\u9ad8\u5c3f\u9178\u8840\u75c7\uff0823.8%\uff09\u548c\u808c\u9178\u78f7\u9178\u6fc0\u9176\u5347\u9ad8\uff0821.4%\uff09\u3002TRAE\u591a\u70ba1 ~ 2\u7d1a\u3002\u22653\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u53cd\u61c9\u5305\u62ec\u8840\u5c0f\u677f\u6e1b\u5c11\uff0838.1%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0821.4%\uff09\u548c\u8ca7\u8840\uff087.1%\uff09\u3002\u8207\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u80fd\u76f8\u95dc\u7684\u4efb\u4f55\u7d1a\u5225\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u5305\u62ec\u9ad8\u8840\u58d3\uff084.8%\uff09\u548c\u623f\u6027\u5fc3\u52d5\u904e\u901f\uff082.4%\uff09\uff0c\u6240\u6709\u9019\u4e9b\u4e8b\u4ef6\u5747\u70ba1\u7d1a\u62162\u7d1a\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dcSAEs\u5305\u62ec\u8840\u5c0f\u677f\u8a08\u6578\u6e1b\u5c11\uff087.1%\uff09\u3001\u8ca7\u8840\u3001\u9aa8\u9ad3\u6291\u5236\u548c\u767c\u71b1\uff08\u54042.4%\uff09\u3002\u7121\u6b7b\u4ea1\u5831\u544a\u3002<\/p>\n<p>\u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u80fd\u70ba\u4e8c\u7ddaCP-CML\u60a3\u8005\u63d0\u4f9b\u4e00\u7a2e\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u5c24\u5176\u662f\u5c0d\u65bc\u4e00\u7dda\u4f7f\u7528\u4e8c\u4ee3TKIs\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u3002<\/p>\n<p>\u58c1\u5831\u5c55\u793a\uff1a<\/p>\n<p>Olverembatinib (HQP1351) Overcomes Resistance\/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses\u00a0<br \/>\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u53ef\u514b\u670d\u7d93\u6df1\u5ea6\u6cbb\u7642\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff08CP CML\uff09\u60a3\u8005\u5c0dAsciminib\u548cPonatinib\u7684\u8010\u85e5\/\u4e0d\u8010\u53d7\uff1a\u4f86\u81ea1.5\u5e74\u96a8\u8a2a\u7684\u6700\u65b0\u6578\u64da\u53ca\u7d9c\u5408\u66b4\u9732-\u53cd\u61c9\uff08E-R\uff09\u5206\u6790<\/p>\n<p>\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a<\/p>\n<p>\u6458\u8981\u7de8\u865f\uff1a3151<\/p>\n<p>\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII<\/p>\n<p>\u5831\u544a\u6642\u9593\uff1a<\/p>\n<p>2024\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u53486:00 &#8211; 8:00\uff08\u7f8e\u570b\u897f\u90e8\u6642\u9593\uff09<br \/>2024\u5e7412\u67089\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u534810:00 &#8211; 12:00\uff08\u5317\u4eac\u6642\u9593\uff09<\/p>\n<p>\u7b2c\u4e00\u4f5c\u8005\uff1aMD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\uff08MD Anderson Cancer Center\uff09\u00a0Elias Jabbour\u6559\u6388<\/p>\n<p>\u6838\u5fc3\u8981\u9ede\uff1a<\/p>\n<p>\u7814\u7a76\u4ecb\u7d39\uff1a\u5c0d\u7b2c\u4e09\u4ee3\uff083G\uff09TKI Ponatinib\u548c\/\u6216Asciminib\uff08\u4e00\u7a2e\u7279\u7570\u6027\u9776\u5411ABL \u8089\u8c46\u853b\u9170\u00a0\uff08STAMP\uff09\u7684\u6291\u5236\u5291\uff09\u8010\u85e5\/\u4e0d\u8010\u53d7\u7684CP-CML\u60a3\u8005\u4e9f\u9700\u65b0\u7684\u6cbb\u7642\u9078\u64c7\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u662f\u4e00\u7a2e\u8010\u53d7\u6027\u826f\u597d\u7684TKI\uff0c\u5177\u6709\u514b\u670d\u5176\u4ed6TKI\u8010\u85e5\u7684\u6f5b\u529b\uff0c\u672c\u6b21\u66f4\u65b0\u4ecb\u7d39\u4e86\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u53cd\u8986\u7d93\u6cbb\u7684CP-CML\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u6578\u64da\u3002<\/p>\n<p>\u5165\u7d44\u60a3\u8005\u548c\u7814\u7a76\u65b9\u6cd5\uff1a<\/p>\n<p>\u5165\u7d44\u689d\u4ef6\u70ba\u65e2\u5f80\u63a5\u53d7\u904e\u22652\u7a2eTKIs\u548c\/\u6216\u4e00\u7a2eSTAMP\u6291\u5236\u5291\u6cbb\u7642\u3001\u5165\u7d44\u6642\u5668\u5b98\u529f\u80fd\u826f\u597d\u3001\u4e14\u65e2\u5f80\u6cbb\u7642\u672a\u9054\u5230MMR\u7684\u6210\u4ebaCP-CML\u60a3\u8005\u3002   \u622a\u81f32024\u5e747\u670828\u65e5\uff0c\u5171\u670967\u4f8bCP-CML\u60a3\u8005\u5165\u7d44\uff0c\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u96a8\u8a2a\u6642\u9593\u70ba74.3\uff080.1-217.1\uff09\u5468\uff1b\u4e2d\u4f4d\uff08\u7bc4\u570d\uff09\u5e74\u9f61\u70ba50\uff0821-80\uff09\u6b72\uff1b\u5176\u4e2d38 \uff0856.7%\uff09\u4f8b\u60a3\u8005\u70ba\u7537\u6027\u3002   \u9019\u4e9b\u60a3\u8005\u88ab\u96a8\u6a5f\u5206\u914d\u5230\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\uff0c\u9694\u5929\u53e3\u670d\u4e00\u6b21(QOD)\uff0c28\u5929\u70ba\u4e00\u500b\u9031\u671f\uff0c\u5291\u91cf\u70ba30,40\u621650mg\u3002\u540c\u6642\u6839\u64daT315I\u7a81\u8b8a\u72c0\u614b\u9032\u884c\u5206\u5c64\uff0c\u4e26\u9032\u884c\u5168\u9762\u7684E-R\u5206\u6790\u3002  <\/p>\n<p>\u7642\u6548\u6578\u64da\uff1a<\/p>\n<p>\u517160\u4f8b\u60a3\u8005\u7642\u6548\u53ef\u8a55\u4f30\uff0c\u6240\u6709\u60a3\u8005\u5747\u70ba\u57fa\u7dda\u6642\u7121\u7642\u6548\u3002\u5176\u4e2d35\u4f8b\uff0858.3%\uff09\u60a3\u8005\u5165\u7d44\u6cbb\u7642\u5f8c\u9054\u5230CCyR\uff0c29\/64\uff0845.3%\uff09\u4f8b\u9054\u5230MMR\u300212\u500b\u6708\u6642\uff0c\u6574\u9ad4MMR\u7387\u70ba61.4%\uff0827\/44\uff09\uff0c\u5176\u4e2dT315I\u7a81\u8b8a\u60a3\u8005\u7684CCyR\u7387\u70ba66.7%\uff0c\u800c\u6c92\u6709T315I\u7a81\u8b8a\u60a3\u8005\u7684CCyR\u7387\u70ba54.8%\uff0cMMR\u7387\u5206\u5225\u70ba50.0%\u548c43.5%\u3002   \u572828\u4f8bPonatinib\u6cbb\u7642\u5931\u6557\u7684\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\u53ef\u8a55\u4f30\u7684CP-CML\u60a3\u8005\u4e2d\uff0c\u670915\u4f8b\uff0853.6%\uff09\u9054\u5230CCyR\uff0c23\u4f8b\u65e2\u5f80Ponatinib\u8010\u85e5\u60a3\u8005\u7684CCyR\u7387\u70ba52.2%\uff0812\/23\uff09\uff0c4\u4f8b\u65e2\u5f80Ponatinib\u4e0d\u8010\u53d7\u60a3\u8005\u7684CCyR\u7387\u70ba75.0%\uff083\/4\uff09\u300230\u4f8b\u5148\u524d\u63a5\u53d7\u904ePonatinib\u6cbb\u7642\u7684\u5206\u5b50\u5b78\u7de9\u89e3\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c\u5171\u670940.0%\uff0812\/30\uff09\u9054\u5230MMR\uff0c\u5176\u4e2d23\u4f8b\u65e2\u5f80Ponatinib\u8010\u85e5\u60a3\u8005\u7684MMR\u7387\u70ba47.8%\uff0811\/23\uff09\uff0c\u65e2\u5f806\u4f8bPonatinib\u4e0d\u8010\u53d7\u60a3\u8005\u7684MMR\u7387\u70ba16.7%\uff081\/6\uff09, \u6240\u6709\u60a3\u8005\u5747\u70ba\u57fa\u7dda\u6642\u7121\u7642\u6548\u3002   \u5728Asciminib\u6cbb\u7642\u5931\u6557\u7684\u53ef\u8a55\u4f30\u60a3\u8005\u4e2d\uff0c37.5%\uff086\/16\uff09\u9054\u5230CCyR\uff0c30%\uff086\/20\uff09\u9054\u5230MMR\uff0c\u5176\u4e2d\u65e2\u5f80Asciminib\u8010\u85e5\u7684\u60a3\u8005\u7684CCyR\u7387\u70ba30.8%\uff084\/13\uff09\u3001MMR\u7387\u70ba26.7%\uff084\/15\uff09\uff1b\u65e2\u5f80Asciminib\u4e0d\u8010\u53d7\u60a3\u8005\u7684CCyR\u7387\u70ba50.0%\uff081\/2 )\uff0cMMR\u7387\u70ba25.0%\uff081\/4) \uff0c\u6240\u6709\u60a3\u8005\u5747\u70ba\u57fa\u7dda\u6642\u7121\u7642\u6548\u3002   \u5148\u524d\u540c\u6642\u63a5\u53d7\u904ePonatinib\u548cAsciminib\u6cbb\u7642\u60a3\u8005\u7684CCyR\u7387\u548cMMR\u7387\u5206\u5225\u70ba30%\u548c25%\uff0c\u6240\u6709\u60a3\u8005\u5747\u70ba\u57fa\u7dda\u6642\u7121\u7642\u6548\u3002  <\/p>\n<p>\u5b89\u5168\u6027\u6578\u64da\uff1a\u572866\u4f8b\u60a3\u8005\u4e2d\uff0c62\uff0893.9%\uff09\u4f8b\u5831\u544a\u4e86\u4efb\u4f55\u7d1a\u5225\u7684\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\uff0c\u5176\u4e2d44\uff0866.7%\uff09\u4f8b\u7d93\u6b77\u4e86\u22653\u7d1a\u7684TEAEs\u3002\u517160\uff0890.9%\uff09\u4f8b\u5831\u544a\u4e86\u4efb\u4f55\u7d1a\u5225\u7684\u8207\u6cbb\u7642\u76f8\u95dc\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5e38\u898bTRAEs\uff08\u767c\u751f\u7387\u226520%\uff09\u70ba\u808c\u9178\u6fc0\u9176\u5347\u9ad8\uff0837.9%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\uff0824.2%\uff09\u548c\u8c37\u4e19\u8f49\u6c28\u9176\u5347\u9ad8\uff0822.7%\uff09\u3002<\/p>\n<p>\u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u8010\u53d7\u6027\u826f\u597d\uff0c\u5728\u53cd\u8986\u7d93\u6cbb\u7684CP-CML\u60a3\u8005\u4e2d\u986f\u793a\u51fa\u986f\u8457\u800c\u6301\u4e45\u7684\u6297\u767d\u8840\u75c5\u6d3b\u6027\u3002\u76ee\u524d\u8a3b\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u62db\u52df\u4e2d\u3002<\/p>\n<p>Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed\/Refractory Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia (R\/R Ph+ ALL): First Report from a Phase 1 Study<br \/>\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u806f\u5408Lisaftoclax\uff08APG-2575\uff09\u6cbb\u7642\u5fa9\u767c\/\u96e3\u6cbb\u6027\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08R\/R Ph+ ALL\uff09\u5152\u7ae5\u53ca\u9752\u5c11\u5e74\u60a3\u8005\u7684\u5b89\u5168\u6027\u548c\u7642\u6548\uff1a\u4e00\u9805I\u671f\u81e8\u5e8a\u7814\u7a76\u7684\u9996\u6b21\u5831\u544a\u3002<\/p>\n<p>\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a<\/p>\n<p>\u6458\u8981\u7de8\u865f\uff1a1443<\/p>\n<p>\u5206\u6703\u5834\uff1a613. \u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u540c\u7a2e\u79fb\u690d\u4ee5\u5916\u7684\u7642\u6cd5\uff1a\u58c1\u5831\u5c55\u793aI<\/p>\n<p>\u5831\u544a\u6642\u9593\uff1a2024\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0b\u53485:30 &#8211; 7:30\uff08\u7f8e\u570b\u897f\u90e8\u6642\u9593\uff09\/ 2024\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0a\u53489:30 &#8211; 11:30\uff08\u5317\u4eac\u6642\u9593\uff09<\/p>\n<p>\u7b2c\u4e00\u4f5c\u8005\uff1a\u00a0\u4e2d\u570b\u91ab\u5b78\u79d1\u5b78\u9662\u8840\u6db2\u75c5\u91ab\u9662\u00a0\u5f35\u5a67\u5afd\u6559\u6388<\/p>\n<p>\u6838\u5fc3\u8981\u9ede\uff1a<\/p>\n<p>\u7814\u7a76\u80cc\u666f\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u662f\u65b0\u578b\u4e09\u4ee3TKI\uff0c\u5177\u6709\u826f\u597d\u8010\u53d7\u6027\uff0c\u4e26\u5728\u5df2\u63a5\u53d7\u6df1\u5ea6\u6cbb\u7642\u7684CP-CML\u60a3\u8005\u4e2d\uff08\u7121\u8ad6\u662f\u5426\u6709T315I\u7a81\u8b8a\uff09\u8868\u73fe\u51fa\u5f37\u5927\u4e14\u6301\u4e45\u7684\u6297\u767d\u8840\u75c5\u6d3b\u6027\u3002Lisaftoclax\u662f\u4e00\u7a2e\u65b0\u578bBcl-2\u6291\u5236\u5291\uff0c\u5728\u591a\u7a2e\u8840\u6db2\u60e1\u6027\u816b\u7624\u4e2d\u986f\u793a\u51fa\u6297\u816b\u7624\u6548\u679c\u3002\u76ee\u524d\uff0cR\/R Ph+ ALL\u5152\u7ae5\u60a3\u8005\u5c1a\u7121\u6709\u6548\u6cbb\u7642\u9078\u64c7\u3002\u672c\u7814\u7a76\u65e8\u5728\u63a2\u7d22\u5967\u96f7\u5df4\u66ff\u5c3c\u55ae\u85e5\u6216\u806f\u5408Lisaftoclax\u5728R\/R Ph+ ALL\u5152\u7ae5\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u3001\u6709\u6548\u6027\u53ca\u85e5\u4ee3\u52d5\u529b\u5b78\uff08PK\uff09\u7279\u5fb5\u3002<\/p>\n<p>\u7814\u7a76\u65b9\u6cd5\uff1a<\/p>\n<p>\u9019\u662f\u4e00\u9805\u958b\u653e\u6a19\u7c64\u7684Ib\u671f\u7814\u7a76\uff0c\u5165\u7d44\u7684\u70ba\u5e74\u9f61\u5c0f\u65bc18\u6b72\u7684R\/R Ph+ ALL\u5152\u7ae5\u60a3\u8005\uff0c\u9019\u4e9b\u60a3\u8005\u5c0d\u81f3\u5c11\u4e00\u7a2eTKI\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff08\u5982\u679c\u60a3\u8005\u651c\u5e36T315I\u7a81\u8b8a\uff0c\u5247\u4e0d\u8003\u616e\u65e2\u5f80TKI\u4f7f\u7528\u60c5\u6cc1\uff09\u3002\u60a3\u8005\u9700\u5177\u5099\u8db3\u5920\u7684Karnofsky\/Lansky\u529f\u80fd\u72c0\u614b\u8a55\u5206\u548c\u5668\u5b98\u529f\u80fd\u3002\u60a3\u6709\u8207Ph+ ALL\u7121\u95dc\u7684\u75c7\u72c0\u6027\u4e2d\u6a1e\u795e\u7d93\u7cfb\u7d71\u75be\u75c5\u6216\u986f\u8457\u51fa\u8840\u7684\u60a3\u8005\u88ab\u6392\u9664\u5728\u5916\u3002   \u5967\u96f7\u5df4\u66ff\u5c3c\u4ee5\u6210\u4eba\u7b49\u6548\u5291\u91cf\uff08AED\uff0940 mg\u53e3\u670d\uff0c\u9694\u65e5\u4e00\u6b21\uff0c\u6301\u7e8c2\u5468\uff08\u7b2c1-14\u5929\uff09\u3002\u7136\u5f8c\u540c\u5291\u91cf\u7684\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408Lisaftoclax\uff0c\u5f8c\u8005\u7684\u6307\u5b9a\u5291\u91cf\u70ba200\/400\/600 mg\uff08AED\uff09\uff0c\u6bcf\u65e5\u4e00\u6b21\uff08QD\uff09\uff0c\u7b2c13-42\u5929\uff08\u7b2c13-15\u5929\u97003\u5929\u5291\u91cf\u905e\u589e\uff09\u3002\u5730\u585e\u7c73\u677e\u4ee56 mg\/m\u00b2\/\u5929\u7684\u5291\u91cf\u5f9e\u7b2c15-42\u5929\u6bcf\u65e5\u53e3\u670d\u4e00\u6b21\u3002\u4e3b\u8981\u7d42\u9ede\u5305\u62ec\u5967\u96f7\u5df4\u66ff\u5c3c\u55ae\u85e5\/\u806f\u5408APG-2575\u7684\u5b89\u5168\u6027\u8a55\u4f30\u3001\u7e3d\u53cd\u61c9\u7387\uff08ORR\uff09\u3001\u53ef\u6e2c\u91cf\u7684\u6b98\u7559\u75be\u75c5\uff08MRD\uff09\u9670\u6027\u7387\u3001\u4ee5\u53caPK\u7279\u5fb5\u3002  <\/p>\n<p>\u5165\u7d44\u60c5\u6cc1\uff1a\u5f9e2022\u5e749\u6708\u81f32024\u5e746\u6708\uff0c\u5171\u5165\u7d44\u4e8610\u4f8b\u60a3\u8005\u3002\u4e2d\u4f4d\u5e74\u9f61\uff08\u7bc4\u570d\uff09\u70ba13.0\uff0811-15\uff09\u6b72\uff0c\u5176\u4e2d6\u4f8b\u70ba\u7537\u6027\u3002\u4e2d\u4f4d\u9ad4\u91cd\uff08\u7bc4\u570d\uff09\u70ba49.85\uff0835.9-86.0\uff09kg\u30029\u4f8b\uff0890.0%\uff09\u60a3\u5152\u8868\u9054p190\u8f49\u9304\u672c\uff1b1\u4f8b\uff0810.0%\uff09\u8868\u9054p210\u8f49\u9304\u672c\u3002\u57fa\u7dda\u6642\uff0c3\u4f8b\u60a3\u5152\u651c\u5e36BCR-ABL1\u7a81\u8b8a\uff0c\u5305\u62ec2\u4f8bT315I\u7a81\u8b8a\u548c1\u4f8bF317L\u7a81\u8b8a\u30021\u4f8b\u60a3\u5152\u56e0\u5728\u7b2c1\u7642\u7a0b\u7b2c1\u5929\uff08C1D1\uff09\u767c\u751f\u7672\u7647\u800c\u9000\u51fa\u8a66\u9a57\uff0c9\u4f8b\u60a3\u5152\u88ab\u7d0d\u51653+3\u5291\u91cf\u905e\u589e\u6a21\u578b\uff1a\u6bcf\u7d44\uff08A\u3001B\u548cC\u7d44\uff09\u54043\u4f8b\u60a3\u5152\uff0c\u5206\u5225\u63a5\u53d7200\u3001400\u548c600 mg\uff08AED\uff09\u6307\u5b9a\u5291\u91cf\u7684Lisaftoclax\u3002\u9019\u4e9b\u60a3\u5152\u5b8c\u6210\u4e8642\u5929\u7684\u6cbb\u7642\uff0c\u4e26\u63a5\u53d7\u4e86\u4e3b\u8981\u7d42\u9ede\u8a55\u4f30\u3002<\/p>\n<p>\u7642\u6548\u6578\u64da\uff1a\u57286\u4f8b\u5f62\u614b\u5b78\u53cd\u61c9\u53ef\u8a55\u4f30\u7684\u60a3\u5152\u4e2d\uff0c\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u55ae\u85e5\u6cbb\u7642\u7d50\u675f\u6642\uff08EOM\uff09\uff0c2\u4f8b\u9054\u5230CR\u4f34\u4e0d\u5b8c\u5168\u8840\u7d30\u80de\u6062\u5fa9\uff08CRi\uff09\uff0c2\u4f8b\u9054\u5230\u90e8\u5206\u7de9\u89e3\uff08PR\uff09\uff0cORR\u70ba66.7%\uff1b\u5728\u5967\u96f7\u5df4\u66ff\u5c3c\u548cLisaftoclax\u806f\u5408\u6cbb\u7642\u7d50\u675f\u6642\uff08EOC\uff09\uff0c5\u4f8b\uff0883.3%\uff09\u9054\u5230\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\uff1b\u57287\u4f8b\u5206\u5b50\u5b78\u53ef\u8a55\u4f30\u7684\u60a3\u5152\u4e2d\uff0c\u67095\uff0871.4%\uff09\u4f8b\u9054\u5230\u4e86MRD\u9670\u6027\uff0c\u5176\u4e2d1\u4f8b\u5728EOM\u9054\u5230\uff0c4\u4f8b\u5728EOC\u9054\u5230\u3002<\/p>\n<p>\u5b89\u5168\u6027\u6578\u64da\uff1a10\u4f8b\u60a3\u5152\u4e2d\u67096\u4f8b\u7d93\u6b77\u4e86\u2265 3\u7d1a\u7684\u8840\u6db2\u5b78\u6cbb\u7642\u671f\u9593\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\uff0c\u5305\u62ec\u8ca7\u8840\uff083\/10\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff087\/10\uff09\u548c\u8840\u5c0f\u677f\u6e1b\u5c11\uff083\/10\uff09\uff1b1\u4f8b\u60a3\u5152\u56e03\u7d1a\u4e19\u6c28\u9178\u6c28\u57fa\u8f49\u79fb\u9176\u5347\u9ad8\u800c\u505c\u6b62\u6cbb\u7642\uff0c\u53e61\u4f8b\u60a3\u5152\u5728\u7b2c1\u7642\u7a0b\u7b2c1\u5929\uff08C1D1\uff09\u767c\u751f\u7672\u7647\u4e26\u9000\u51fa\u8a66\u9a57\u3002<\/p>\n<p>PK\uff1a\u521d\u6b65PK\u5206\u6790\u986f\u793a\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u548cLisaftoclax\u5728\u5152\u7ae5\u548c\u6210\u4eba\u4e2d\u5177\u6709\u76f8\u4f3c\u7684PK\u7279\u5fb5\u548c\u53ef\u6bd4\u7684\u85e5\u7269\u66b4\u9732\uff0c\u7d93\u904e\u591a\u6b21\u7d66\u85e5\u5f8c\u672a\u898b\u986f\u8457\u84c4\u7a4d\u3002\u4e14\u5967\u96f7\u5df4\u66ff\u5c3c\u548cLisaftoclax\u4e4b\u9593\u672a\u89c0\u5bdf\u5230\u85e5\u7269\u76f8\u4e92\u4f5c\u7528\u3002<\/p>\n<p>\u7d50\u8ad6\uff1a\u521d\u6b65\u6578\u64da\u8868\u660e\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408Lisaftoclax\u70baR\/R Ph+ ALL\u60a3\u5152\u63d0\u4f9b\u4e86\u4e00\u7a2e\u5b89\u5168\u4e14\u6709\u6548\u7684\u6cbb\u7642\u9078\u64c7\u3002\u8a72\u65b9\u6848\u5728\u7121\u9700\u5f37\u5316\u7642\u6216\u514d\u75ab\u6cbb\u7642\u7684\u60c5\u6cc1\u4e0b\uff0c\u5be6\u73fe\u4e8683.3%\u7684CR\u7387\u548c71.4%\u7684MRD\u8f49\u9670\u7387\u3002\u76ee\u524d\uff0c\u8a72\u7814\u7a76\u6b63\u8655\u65bc\u5291\u91cf\u64f4\u5c55\u968e\u6bb5\u3002<\/p>\n<p>\u95dc\u65bc\u4e9e\u76db\u91ab\u85e5<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\u3002<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216 MDM2-p53\u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\uff0c\u70ba\u5168\u7403\u552f\u4e00\u5728\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u9818\u57df\u5747\u6709\u81e8\u5e8a\u958b\u767c\u54c1\u7a2e\u7684\u5275\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u5df2\u5728\u4e2d\u570b\u3001\u7f8e\u570b\u3001\u6fb3\u5927\u5229\u4e9e\u53ca\u6b50\u6d32\u958b\u5c5540\u591a\u9805\u81e8\u5e8a\u8a66\u9a57\uff0c\u5176\u4e2d\u5305\u62ec13\u9805\u8a3b\u518a\u81e8\u5e8a\u7814\u7a76\uff08\u5df2\u5b8c\u6210\/\u9032\u884c\u4e2d\/\u64ec\u555f\u52d5\uff09\u3002<\/p>\n<p>\u7528\u65bc\u6cbb\u7642\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u66fe\u7372\u4e2d\u570b\u570b\u5bb6\u85e5\u54c1\u76e3\u7763\u7ba1\u7406\u5c40\u65b0\u85e5\u5be9\u8a55\u4e2d\u5fc3\uff08CDE\uff09\u7d0d\u5165\u512a\u5148\u5be9\u8a55\u548c\u7a81\u7834\u6027\u6cbb\u7642\u54c1\u7a2e\uff0c\u4e26\u5df2\u5728\u4e2d\u570b\u7372\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u500b\u4e0a\u5e02\u54c1\u7a2e\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b\u5df2\u88ab\u6210\u529f\u7d0d\u5165\u300a\u570b\u5bb6\u57fa\u672c\u91ab\u7642\u4fdd\u96aa\u3001\u5de5\u50b7\u4fdd\u96aa\u548c\u751f\u80b2\u4fdd\u96aa\u85e5\u54c1\u76ee\u9304\u300b\u3002\u8a72\u54c1\u7a2e\u9084\u7372\u5f97\u4e86\u7f8e\u570bFDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u3001\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u4ee5\u53ca\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\u3002<\/p>\n<p>\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u500b\u5728\u7814\u65b0\u85e5\u7372\u5f9716\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u7bc4\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u4f48\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u4ee5\u53caMD\u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\uff08MD Anderson Cancer Center\uff09\u3001\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u4fc2\u3002<\/p>\n<p>\u4e9e\u76db\u91ab\u85e5\u5df2\u69cb\u5efa\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n<p>\u524d\u77bb\u6027\u8072\u660e<\/p>\n<p>\u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u8207\u672c\u6587\u4f5c\u51fa\u8a72\u9673\u8ff0\u7576\u65e5\u7684\u4e8b\u4ef6\u6216\u8cc7\u6599\u6709\u95dc\u3002\u9664\u6cd5\u5f8b\u898f\u5b9a\u5916\uff0c\u65bc\u4f5c\u51fa\u524d\u77bb\u6027\u9673\u8ff0\u7576\u65e5\u4e4b\u5f8c\uff0c\u7121\u8ad6\u662f\u5426\u51fa\u73fe\u65b0\u8cc7\u6599\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u6211\u5011\u4e26\u7121\u8cac\u4efb\u66f4\u65b0\u6216\u516c\u958b\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u9810\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8acb\u7d30\u95b1\u672c\u6587\uff0c\u4e26\u7406\u89e3\u6211\u5011\u7684\u5be6\u969b\u672a\u4f86\u696d\u7e3e\u6216\u8868\u73fe\u53ef\u80fd\u8207\u9810\u671f\u6709\u91cd\u5927\u5dee\u7570\u3002\u672c\u6587\u5167\u6240\u6709\u9673\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u767c\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u4f86\u767c\u5c55\u800c\u51fa\u73fe\u8b8a\u52d5\u3002<\/p>","protected":false},"excerpt":{"rendered":"<p>\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2024\u5e7411\u67086\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c66\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a\u3002\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c7\u5e74\u5165\u9078ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\uff0c\u5145\u5206\u9ad4\u73fe\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u5176\u7642\u6548\u548c\u5b89\u5168\u6027\u7684\u8a8d\u53ef\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\uff0c\u516c\u53f8\u56db\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u3001APG- &#8230; <\/p>\n<p class=\"read-more-container\"><a title=\"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a\" class=\"read-more button\" href=\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990#more-22990\" aria-label=\"\u66f4\u591a \u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a\">\u4e86\u89e3\u8a73\u60c5<\/a><\/p>\n","protected":false},"author":0,"featured_media":22991,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_generate-full-width-content":"","spay_email":"","footnotes":""},"categories":[1],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a - \u9999\u6e2f\u7279\u8a31\u7d93\u71df<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a - \u9999\u6e2f\u7279\u8a31\u7d93\u71df\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2024\u5e7411\u67086\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c66\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a\u3002\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c7\u5e74\u5165\u9078ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\uff0c\u5145\u5206\u9ad4\u73fe\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u5176\u7642\u6548\u548c\u5b89\u5168\u6027\u7684\u8a8d\u53ef\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\uff0c\u516c\u53f8\u56db\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u3001APG- ... \u4e86\u89e3\u8a73\u60c5\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990\" \/>\n<meta property=\"og:site_name\" content=\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-05T22:08:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a\",\"datePublished\":\"2024-11-05T22:08:00+00:00\",\"dateModified\":\"2024-11-05T22:08:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990\"},\"wordCount\":721,\"publisher\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#organization\"},\"articleSection\":[\"\u672a\u5206\u985e\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990\",\"url\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990\",\"name\":\"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a - \u9999\u6e2f\u7279\u8a31\u7d93\u71df\",\"isPartOf\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#website\"},\"datePublished\":\"2024-11-05T22:08:00+00:00\",\"dateModified\":\"2024-11-05T22:08:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\/\/www.franchise.com.hk\/zh-hans\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#website\",\"url\":\"https:\/\/www.franchise.com.hk\/zh-hans\",\"name\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\",\"description\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df | Franchise HK\",\"publisher\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.franchise.com.hk\/zh-hans?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#organization\",\"name\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\",\"url\":\"https:\/\/www.franchise.com.hk\/zh-hans\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#\/schema\/logo\/image\/\",\"url\":\"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1\",\"contentUrl\":\"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1\",\"width\":350,\"height\":76,\"caption\":\"\u9999\u6e2f\u7279\u8a31\u7d93\u71df\"},\"image\":{\"@id\":\"https:\/\/www.franchise.com.hk\/zh-hans#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a - \u9999\u6e2f\u7279\u8a31\u7d93\u71df","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990","og_locale":"zh_CN","og_type":"article","og_title":"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a - \u9999\u6e2f\u7279\u8a31\u7d93\u71df","og_description":"\u7f8e\u570b\u99ac\u91cc\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2024\u5e7411\u67086\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u4f48\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c66\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a\u3002\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c7\u5e74\u5165\u9078ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\uff0c\u5145\u5206\u9ad4\u73fe\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u5176\u7642\u6548\u548c\u5b89\u5168\u6027\u7684\u8a8d\u53ef\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\uff0c\u516c\u53f8\u56db\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u3001APG- ... \u4e86\u89e3\u8a73\u60c5","og_url":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990","og_site_name":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df","article_published_time":"2024-11-05T22:08:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"4 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990#article","isPartOf":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990"},"author":{"name":"","@id":""},"headline":"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a","datePublished":"2024-11-05T22:08:00+00:00","dateModified":"2024-11-05T22:08:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990"},"wordCount":721,"publisher":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans#organization"},"articleSection":["\u672a\u5206\u985e"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990","url":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990","name":"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a - \u9999\u6e2f\u7279\u8a31\u7d93\u71df","isPartOf":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans#website"},"datePublished":"2024-11-05T22:08:00+00:00","dateModified":"2024-11-05T22:08:00+00:00","breadcrumb":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.franchise.com.hk\/zh-hans\/%e3%80%902024-ash%e3%80%91%e4%b8%83%e9%80%a3%e5%86%a0%ef%bc%81%e8%80%90%e7%ab%8b%e5%85%8b%e6%94%9c%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e7%ac%ac%e4%b8%83%e6%ac%a1%e5%85%a5%e9%81%b8%ef%bc%8c%e5%85%b6\/22990#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/www.franchise.com.hk\/zh-hans"},{"@type":"ListItem","position":2,"name":"\u30102024 ASH\u3011\u4e03\u9023\u51a0\uff01\u8010\u7acb\u514b\u651c\u591a\u9805\u7814\u7a76\u7b2c\u4e03\u6b21\u5165\u9078\uff0c\u5176\u4e2d1\u9805\u7372\u53e3\u982d\u5831\u544a"}]},{"@type":"WebSite","@id":"https:\/\/www.franchise.com.hk\/zh-hans#website","url":"https:\/\/www.franchise.com.hk\/zh-hans","name":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df","description":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df | Franchise HK","publisher":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.franchise.com.hk\/zh-hans?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/www.franchise.com.hk\/zh-hans#organization","name":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df","url":"https:\/\/www.franchise.com.hk\/zh-hans","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/www.franchise.com.hk\/zh-hans#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2022\/05\/cropped-cropped-franchise-logo-02-e1652686851566-2.png?fit=350%2C76&ssl=1","width":350,"height":76,"caption":"\u9999\u6e2f\u7279\u8a31\u7d93\u71df"},"image":{"@id":"https:\/\/www.franchise.com.hk\/zh-hans#\/schema\/logo\/image\/"}}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.franchise.com.hk\/wp-content\/uploads\/2024\/11\/Ascentage_Pharma_Logo-3h0Z4n.jpeg?fit=597%2C115&ssl=1","_links":{"self":[{"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/posts\/22990"}],"collection":[{"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/comments?post=22990"}],"version-history":[{"count":0,"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/posts\/22990\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/media\/22991"}],"wp:attachment":[{"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/media?parent=22990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/categories?post=22990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.franchise.com.hk\/zh-hans\/wp-json\/wp\/v2\/tags?post=22990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}